Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Flow Cytometry01:23

Flow Cytometry

The development of flow cytometry techniques began in 1934 with initial attempts by Andrew Moldavan, a bacteriologist who counted the cells in a flowing capillary system. Moldavan pumped cells through a capillary tube focused under a microscope for visualization. The invention of photometry allowed the measurement of differentially-stained cells, and Louis Kamentsky developed the first multiparameter flow cytometer in 1965 to identify and count the cancer cells in cervical tissue specimens.
In...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated Microfluidic Platform for Longitudinal Imaging, Functional Assays, and Downstream Proteomics in C. elegans.

Small (Weinheim an der Bergstrasse, Germany)·2025
Same author

The Juvenile Parkinson's Disease Mutation C212Y Impairs Mitochondrial Homeostasis in a Caenorhabditis elegans Model.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2025
Same author

Pneumonitis after chemoradiation followed by durvalumab for locally advanced lung cancer: predictors and effect on survival.

The British journal of radiology·2025
Same author

Evaluation and modification of tumor cell isolation techniques from malignant effusions for rapid drug sensitivity testing.

Molecular oncology·2025
Same author

Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.

Oncotarget·2025
Same author

SUMO-mediated regulation of H3K4me3 reader SET-26 controls germline development in C. elegans.

PLoS biology·2025

Related Experiment Video

Updated: Jul 14, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K

OncoFlow: A multiplexed microfluidic platform for personalized drug sensitivity assessment.

Matan Krasner1, Efrat Barbiro-Michaely1, Ulrike Bening Abu-Shach2

  • 1The Mina & Everard Goodman Faculty of Life Sciences and the Institute for Nanotechnology and Advanced Materials, Bar Ilan University, Ramat-Gan, Israel.

New Biotechnology
|March 12, 2025
PubMed
Summary

OncoFlow, a microfluidic platform, assesses patient tumor cell drug response for personalized non-small cell lung adenocarcinoma (NSCLC) treatment. It revealed varied sensitivities to crizotinib and resistance to alectinib in NSCLC pleural effusion samples.

Keywords:
AlectinibCrizotinibEML4-ALK non-small cell lung adenocarcinomaFunctional AssayPersonalized medicinePleural Effusion

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

4.7K

Related Experiment Videos

Last Updated: Jul 14, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

4.7K

Area of Science:

  • Oncology
  • Biotechnology
  • Microfluidics

Background:

  • Precision medicine advances like biomarker-guided treatments and next-generation sequencing (NGS) have limitations.
  • A gap exists between tumor genomic characterization and functional behavior, necessitating functional assays.
  • There is a growing need for personalized cancer treatment strategies based on individual patient responses.

Purpose of the Study:

  • To develop and validate OncoFlow, an automated microfluidic platform for functional viability assays.
  • To assess the efficacy of OncoFlow in customizing treatment options for non-small cell lung adenocarcinoma (NSCLC) patients.
  • To evaluate patient tumor cell sensitivity to specific tyrosine kinase inhibitors using the OncoFlow system.

Main Methods:

  • Development of OncoFlow, an integrated microfluidic platform for automated viability assays.
  • Validation of the assay using the NCI-H2228 adenocarcinoma cell line (EML4-ALK fusion) with alectinib and crizotinib.
  • Testing of pleural effusion samples from six NSCLC patients, including four with EML4-ALK rearrangement, on the OncoFlow system.

Main Results:

  • The OncoFlow assay's reliability was confirmed by its consistency with conventional cell culture methods.
  • Patient-derived NSCLC cells showed varied sensitivities to crizotinib.
  • All tested NSCLC patient samples exhibited resistance to alectinib.

Conclusions:

  • OncoFlow effectively assesses functional drug responses in patient tumor cells.
  • The platform demonstrates potential for enhancing physician decision-making in NSCLC treatment.
  • OncoFlow can contribute to the customization of cancer treatment plans and improved patient outcomes.